DDInter557 DDInter518
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Dihydroergotamine {u} (Compound) binds {v} (Gene) HTR2B
HTR2B {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dihydroergotamine {u} (Compound) binds {v} (Gene) HTR2B
HTR2B {u} (Gene) is bound by {v} (Compound) Aripiprazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) HTR2C
HTR2C {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dihydroergotamine {u} (Compound) binds {v} (Gene) HTR2B
HTR2B {u} (Gene) is bound by {v} (Compound) Cyproheptadine
Cyproheptadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} (Compound) resembles {v} (Compound) Methysergide
Methysergide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ioflupane I-123
Ioflupane I-123 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Tamoxifen
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dihydroergotamine {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) is bound by {v} (Compound) Metamfetamine
Metamfetamine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dihydroergotamine (Compound) binds HTR2B (Gene) and HTR2B (Gene) is bound by Dexfenfluramine (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Dihydroergotamine (Compound) binds HTR2B (Gene) and HTR2B (Gene) is bound by Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Ergotamine (Compound) and Ergotamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) binds HTR2C (Gene) and HTR2C (Gene) is bound by Dexfenfluramine (Compound)
Dihydroergotamine (Compound) binds HTR2B (Gene) and HTR2B (Gene) is bound by Cyproheptadine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine (Compound) resembles Methysergide (Compound) and Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123 and Ioflupane I-123 may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Dexfenfluramine
Dihydroergotamine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Metamfetamine (Compound) and Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine